Gradel, Kim OrenPóvoa, PedroPovoa, PedroGarvik, Olav SivertsenVinholt, Pernille JustNielsen, Stig LønbergJensen, Thøger GormChen, MingDessau, Ram BennyMøller, Jens KjølsethCoia, John EugenioLjungdalh, Pernille SanbergLassen, Annmarie TouborgFrederiksen, Henrik2020-04-062020-04-062020-03-241471-2407PURE: 17642057PURE UUID: cf370ed2-b560-4a96-936f-7f53ad7155b8Scopus: 85082380857PubMed: 32209087http://hdl.handle.net/10362/95784BACKGROUND: No study has evaluated C-reactive protein (CRP) and plasma albumin (PA) levels longitudinally in patients with acute myeloid leukaemia (AML). METHODS: We studied defined events in 818 adult patients with AML in relation to 60,209 CRP and PA measures. We investigated correlations between CRP and PA levels and daily CRP and PA levels in relation to AML diagnosis, AML relapse, or bacteraemia (all ±30 days), and death (─30-0 days). RESULTS: On the AML diagnosis date (D0), CRP levels increased with higher WHO performance score (PS), e.g. patients with PS 3/4 had 68.1 mg/L higher CRP compared to patients with PS 0, adjusted for relevant covariates. On D0, the PA level declined with increasing PS, e.g. PS 3/4 had 7.54 g/L lower adjusted PA compared to PS 0. CRP and PA levels were inversely correlated for the PA interval 25-55 g/L (R = - 0.51, p < 10-5), but not for ≤24 g/L (R = 0.01, p = 0.57). CRP increases and PA decreases were seen prior to bacteraemia and death, whereas no changes occurred up to AML diagnosis or relapse. CRP increases and PA decreases were also found frequently in individuals, unrelated to a pre-specified event. CONCLUSIONS: PA decrease is an important biomarker for imminent bacteraemia in adult patients with AML.11411311engAcute myeloid leukaemiaC-reactive proteinInfectionInflammationPlasma albuminGeneticsOncologyCancer ResearchSDG 3 - Good Health and Well-beingjournal article10.1186/s12885-020-06754-zhttps://www.scopus.com/pages/publications/85082380857